RU2016104044A - Ингибиторы усилителя zeste гомолога 2 - Google Patents
Ингибиторы усилителя zeste гомолога 2 Download PDFInfo
- Publication number
- RU2016104044A RU2016104044A RU2016104044A RU2016104044A RU2016104044A RU 2016104044 A RU2016104044 A RU 2016104044A RU 2016104044 A RU2016104044 A RU 2016104044A RU 2016104044 A RU2016104044 A RU 2016104044A RU 2016104044 A RU2016104044 A RU 2016104044A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844540P | 2013-07-10 | 2013-07-10 | |
| US61/844,540 | 2013-07-10 | ||
| PCT/IB2014/062983 WO2015004618A1 (en) | 2013-07-10 | 2014-07-09 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016104044A true RU2016104044A (ru) | 2017-08-15 |
Family
ID=51212901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016104044A RU2016104044A (ru) | 2013-07-10 | 2014-07-09 | Ингибиторы усилителя zeste гомолога 2 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9556157B2 (enExample) |
| EP (1) | EP3019494B1 (enExample) |
| JP (1) | JP2016523955A (enExample) |
| KR (1) | KR20160030221A (enExample) |
| CN (1) | CN105473580A (enExample) |
| AU (1) | AU2014288839B2 (enExample) |
| CA (1) | CA2917463A1 (enExample) |
| ES (1) | ES2640386T3 (enExample) |
| RU (1) | RU2016104044A (enExample) |
| WO (1) | WO2015004618A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| MA40848A (fr) * | 2014-10-28 | 2021-05-05 | Glaxosmithkline Ip No 2 Ltd | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017079757A1 (en) * | 2015-11-06 | 2017-05-11 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
| AU2017330443B2 (en) | 2016-09-26 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Chromobox protein inhibitors and uses thereof |
| BR112019014924A2 (pt) | 2017-01-19 | 2020-03-31 | St. Marianna University School Of Medicine | Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN114269748A (zh) | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| CA3249707A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| JP4664597B2 (ja) | 2002-04-17 | 2011-04-06 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9730925B2 (en) * | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| WO2013075084A1 (en) * | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2836216B1 (en) | 2012-04-13 | 2022-06-08 | Epizyme, Inc. | Combination therapy for treating cancer |
| ES2617379T3 (es) | 2012-04-13 | 2017-06-16 | Epizyme, Inc. | Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| BR112015008480A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | compostos de benzeno substituído |
| RU2015127822A (ru) | 2012-12-13 | 2017-01-16 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Ингибиторы энхансера гомолога 2 белка zeste |
| CA2894222A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
-
2014
- 2014-07-09 CA CA2917463A patent/CA2917463A1/en not_active Abandoned
- 2014-07-09 RU RU2016104044A patent/RU2016104044A/ru not_active Application Discontinuation
- 2014-07-09 US US14/898,178 patent/US9556157B2/en not_active Expired - Fee Related
- 2014-07-09 WO PCT/IB2014/062983 patent/WO2015004618A1/en not_active Ceased
- 2014-07-09 ES ES14741958.4T patent/ES2640386T3/es active Active
- 2014-07-09 AU AU2014288839A patent/AU2014288839B2/en not_active Ceased
- 2014-07-09 CN CN201480046665.4A patent/CN105473580A/zh active Pending
- 2014-07-09 JP JP2016524931A patent/JP2016523955A/ja active Pending
- 2014-07-09 KR KR1020167002906A patent/KR20160030221A/ko not_active Withdrawn
- 2014-07-09 EP EP14741958.4A patent/EP3019494B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015004618A1 (en) | 2015-01-15 |
| JP2016523955A (ja) | 2016-08-12 |
| EP3019494B1 (en) | 2017-06-21 |
| US9556157B2 (en) | 2017-01-31 |
| US20160130261A1 (en) | 2016-05-12 |
| CN105473580A (zh) | 2016-04-06 |
| CA2917463A1 (en) | 2015-01-15 |
| KR20160030221A (ko) | 2016-03-16 |
| ES2640386T3 (es) | 2017-11-02 |
| AU2014288839B2 (en) | 2017-02-02 |
| AU2014288839A1 (en) | 2016-01-28 |
| EP3019494A1 (en) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015127822A (ru) | Ингибиторы энхансера гомолога 2 белка zeste | |
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| RU2016138676A (ru) | Ингибиторы усилителя zeste гомолога 2 | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| RU2016108987A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| JP2016517878A5 (enExample) | ||
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| AR092661A1 (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1) | |
| EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
| JP2012532137A5 (enExample) | ||
| JP2015529229A5 (enExample) | ||
| JP2013510124A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| PH12020551471A1 (en) | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| JP2015504091A5 (enExample) | ||
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| JP2019516739A5 (enExample) | ||
| RU2015150120A (ru) | Соединение дикарбоновой кислоты | |
| JP2016540028A5 (enExample) | ||
| PH12015501560A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180808 |